Microstructural changes after half-dose photodynamic therapy in patients with chronic central serous chorioretinopathy

被引:2
|
作者
Esen, Ebru [1 ]
Sizmaz, Selcuk [1 ]
Demircan, Nihal [1 ]
机构
[1] Cukurova Univ, Sch Med, Dept Ophthalmol, Adana, Turkey
关键词
Central serous chorioretinopathy; Photodynamic therapy; Optical coherence tomography; Outer nuclear layer; Choroidal thickness; OPTICAL COHERENCE TOMOGRAPHY; SUBFOVEAL CHOROIDAL THICKNESS; PHOTORECEPTOR OUTER SEGMENT; MORPHOLOGIC CHANGES; NUCLEAR LAYER; VERTEPORFIN; EYES; OUTCOMES;
D O I
10.1016/j.pdpdt.2021.102347
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: To evaluate the retinal and choroidal microstructural changes at fovea after half-dose photodynamic therapy (PDT) in patients with chronic central serous chorioretinopathy (CSC), using optical coherence tomography (OCT). Methods: The study included 35 eyes with unilateral chronic CSC treated with half-dose PDT. The foveal outer nuclear layer (ONL) and subfoveal choroidal thickness (SFCT) in the affected eyes were compared with baseline measurements at month 1, 3, and 6 after half-dose PDT, and those of the healthy contralateral eyes. Results: The mean baseline ONL thickness of the affected eyes was thinner compared to unaffected fellow eyes (66.9 +/- 16.5 mu m vs 111.5 +/- 11.6 mu m, p<0.001), and increased significantly to 68.6 +/- 17.0 mu m at month 3 and 68.9 +/- 17.3 mu m at month 6 after treatment (p = 0.025 and p = 0.014 respectively). The mean baseline SFCT of the affected eyes was thicker compared to unaffected fellow eyes (399.9 +/- 87.0 mu m vs 338.2 +/- 75.4 mu m, p<0.001), and decreased significantly after treatment at month 1, 3, and 6 (374.0 +/- 84.8 mu m, 369.7 +/- 81.8 mu m, 367.3 +/- 80.8 mu m respectively, p<0.001 for all). The responder group (n = 26), in which subretinal fluid was completely resorbed, showed a significant increase in ONL thickness and decrease in SFCT after treatment, whereas in the non-responder group (n = 9) ONL thickness and SFCT did not differ after treatment. Conclusions: In CSC patients, significant changes are observed in foveal ONL thickness and SFCT after half-dose PDT. ONL thickness and SFCT are suggested to be considered in the OCT examinations of CSC patients.
引用
收藏
页数:6
相关论文
共 50 条
  • [31] Structural analyses of choroid after half-dose verteporfin photodynamic therapy for central serous chorioretinopathy
    Izumi, Takahiko
    Koizumi, Hideki
    Maruko, Ichiro
    Takahashi, Yohei
    Sonoda, Shozo
    Sakamoto, Taiji
    Iida, Tomohiro
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2017, 101 (04) : 433 - 437
  • [32] Improvement of Low Luminance Visual Acuity in Patients with Chronic Central Serous Chorioretinopathy after Half-Dose Verteporfin Photodynamic Therapy
    Fujita, Kyoko
    Shinoda, Kei
    Imamura, Yutaka
    Matsumoto, Celso Soiti
    Oda, Koichi
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (12) : 1 - 7
  • [33] Photodynamic therapy with half dose of verteporfin in patients with chronic central serous chorioretinopathy
    Haas, A.
    Mossboeck, G.
    Stangl, C.
    Wohlfart, C.
    Bachernegg, M.
    Fuerschuss-Wolff, P.
    Weger, M.
    SPEKTRUM DER AUGENHEILKUNDE, 2006, 20 (05) : 227 - 230
  • [34] Long-term results of half-dose photodynamic therapy for chronic central serous chorioretinopathy with contrast sensitivity changes
    Karakus, S. H.
    Basarir, B.
    Pinarci, E. Y.
    Kirandi, E. U.
    Demirok, A.
    EYE, 2013, 27 (05) : 612 - 620
  • [35] Long-term results of half-dose photodynamic therapy for chronic central serous chorioretinopathy with contrast sensitivity changes
    S H Karakus
    B Basarir
    E Y Pinarci
    E U Kirandi
    A Demirok
    Eye, 2013, 27 : 612 - 620
  • [36] Comparative efficacy of brolucizumab, half-dose photodynamic therapy, and aflibercept in managing chronic central serous chorioretinopathy
    Yu-Te Huang
    Peng-Tai Tien
    Po-Yu Chen
    Chi-Lan Yang
    San-Ni Chen
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2024, 262 : 1755 - 1763
  • [37] Choroidal neovascularization secondary to half-dose photodynamic therapy for chronic central serous chorioretinopathy A case report
    Zhang, Zhengwei
    Bao, Xiaona
    Wu, Zhifeng
    Zhang, Jie
    MEDICINE, 2021, 100 (07) : E24790
  • [38] Comparative efficacy of brolucizumab, half-dose photodynamic therapy, and aflibercept in managing chronic central serous chorioretinopathy
    Huang, Yu-Te
    Tien, Peng-Tai
    Chen, Po-Yu
    Yang, Chi-Lan
    Chen, San-Ni
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2024, 262 (06) : 1755 - 1763
  • [39] One-Year Outcomes with Half-Dose Verteporfin Photodynamic Therapy for Chronic Central Serous Chorioretinopathy
    Fujita, Kyoko
    Imamura, Yutaka
    Shinoda, Kei
    Matsumoto, Celso Soiti
    Mizutani, Yoshihiro
    Hashizume, Kouhei
    Mizota, Atsushi
    Yuzawa, Mitsuko
    OPHTHALMOLOGY, 2015, 122 (03) : 555 - 561
  • [40] Safety and efficacy of fovea-involving half-dose photodynamic therapy for chronic central serous chorioretinopathy
    Feenstra, Helena Margaret Anthonia
    Diederen, Roselie M. H.
    Lamme, Martine J. C. M.
    Fauser, Sascha
    Downes, Susan M.
    Schlingemann, Reinier O.
    Hoyng, Carel C. B.
    van Dijk, Elon H. C.
    Boon, Camiel J. F.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2022, 63 (07)